X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The drug's preclinical and clinical pharmacology supports the potential of HBI-3000 (sulcardine sulfate) to restore sinus rhythm in Atrial Fibrillation. The drug has demonstrated a low risk for proarrhythmia in preclinical testing.
Lead Product(s): Sulcardine Sulfate
Therapeutic Area: Cardiology/Vascular Diseases Product Name: HBI-3000
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 14, 2022
Details:
The drug’s preclinical and clinical pharmacology supports the potential of HBI-3000 to restore sinus rhythm in Atrial Fibrillation. The drug has demonstrated a low risk for proarrhythmia in preclinical testing.
Lead Product(s): Sulcardine Sulfate
Therapeutic Area: Cardiology/Vascular Diseases Product Name: HBI-3000
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 17, 2022
Details:
Data from the registration study of HBI-8000 has demonstrated clinically meaningful responses despite the advanced stage of disease and acceptable safety profile to address an important unmet medical need in this patient population.
Lead Product(s): Chidamide
Therapeutic Area: Oncology Product Name: HBI-8000
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Shenzhen Chipscreen Biosciences
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 30, 2021
Details:
Hiyasta (HBI-8000) is an epigenetic immunomodulator approved for the treatment of lymphoma and metastatic breast cancer. it targets class I histone deacetylases and suppresses expression of viral oncogene HTLV-I bZIP factor, NF-kB and the inflammasome in ATLL cells.
Lead Product(s): Tucidinostat
Therapeutic Area: Oncology Product Name: Hiyasta
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2021
Details:
HBI-2376 is an oral small molecule inhibitor of SHP2 for multiple tumor types whose cellular growth is dependent on MAPK pathway. Both in vitro and in vivo studies HBI-2376 has shown a very good PK and safety profile.
Lead Product(s): HBI-2376
Therapeutic Area: Oncology Product Name: GH21
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Genhouse Bio
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 31, 2021
Details:
Study confirms tolerability and significant anti-tumor activity of HBI-8000 in combination with nivolumab in checkpoint naive melanoma patients.
Lead Product(s): Chidamide,Nivolumab
Therapeutic Area: Oncology Product Name: HBI-8000
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2020
Details:
HBI-8000 is an epigenetic immunomodulator approved for the treatment of lymphoma and metastatic breast cancer in China. HBI-8000 targets class I histone deacetylase and suppresses the expression of the viral oncogene HTLV-I bZIP factor, NF-kB and the inflammasome in ATL cells.
Lead Product(s): Chidamide
Therapeutic Area: Oncology Product Name: HBI-8000
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2020
Details:
HUYA Bioscience has exclusively licensed worldwide rights, outside of China, to the SHP2 inhibitor, HBI-2376, from Suzhou GenHouse. SHP2 is an important component of RAS signaling pathway leading to activation of ERK/MAPK pathways in a variety of cancer cells.
Lead Product(s): HBI-2376
Therapeutic Area: Oncology Product Name: HBI-2376
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Suzhou GenHouse
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 04, 2020
Details:
Phase 2 trial will test the unique multi-channel ion blocker in acute atrial fibrillation.
Lead Product(s): Sulcardine Sulfate
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 28, 2020
Details:
HUYABIO will complete the development of HBI-8000 for PTCL and ATL in Japan for commercialization by Meiji who will hold exclusive sales and marketing rights.
Lead Product(s): Tucidinostat
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Meiji Seika Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 08, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
